DNMT3A and hematologic disorder: Present data suggest that in contrast to hematologic malignancies where inactivating DNMT3A mutations reveal a tumor suppressor role (Fernandez et al, 2012; Yang et al, 2015), DNMT3A plays an oncogenic role as a key effector of VEGFA‐driven ovarian CSC expansion.